Ependymoblastoma associated with prenatal exposure to diphenylhydantoin and methylphenobarbitone.
Ependymoblastoma developed in a 28-month-old girl whose epileptic mother took diphenylhydantoin and methylphenobarbitone throughout pregnancy. The child was also shown to be a genetic carrier for ornithine transcarbamylase deficiency, an x-linked inborn error of urea cycle metabolism. The possibility of transplacental carcinogenesis should be considered, as other juvenile embryonic tumors such as neuroblastoma, melanotic neuroectodermal tumor, and mesenchymoma have been reported in offspring after diphenylhydantoin use by the mother during pregnancy.
D001932:Brain Neoplasms / Q000139:chemically induced*; D002675:Child, Preschool; D004806:Ependymoma / Q000139:chemically induced*; D005260:Female; D005625:Frontal Lobe; D006579:Heterozygote; D006801:Humans; D008431:Maternal-Fetal Exchange; D008618:Mephobarbital / Q000009:adverse effects*; D020163:Ornithine Carbamoyltransferase Deficiency Disease; D010672:Phenytoin / Q000009:adverse effects*; D011247:Pregnancy
D008618:Mephobarbital; D010672:Phenytoin